Credit Suisse upgrades Ranbaxy to 'neutral'

Wed Feb 20, 2013 11:48am IST

Related Topics

Stocks

   

Reuters Market Eye - Credit Suisse upgrades Ranbaxy Laboratories Ltd (RANB.NS) to "neutral" from "underperform".

The investment bank says the possible penalty related to the recall of generic Lipitor last year in the United states was likely to be "low." The stock has already factored in the impact.

It adds share prices have also factored in a cash loss on currency options which Ranbaxy may report during its fourth quarter earnings, scheduled to be released on February 26.

Credit Suisse lowers its EPS estimates for the company for calendar years 2013 and 2014 by 6 percent and 11 percent respectively and cuts its target price by 5 percent to 435 rupees.

(Reporting by Abhishek Vishnoi)

FILED UNDER:

Economic Pulse

REUTERS SHOWCASE

Nifty Above 8,600

Nifty Above 8,600

Nifty hits record high above 8,600; state-run lenders gain  Full Article 

Indian in Iraq

Indian in Iraq

India says no contact with 39 men held by Islamic State in Iraq.  Full Article 

Sahara Issue

Sahara Issue

Sahara looks to raise $650 million loan to fund bail.  Full Article 

Bhopal Tragedy

Bhopal Tragedy

Bhopal's toxic legacy lives on, 30 years after industrial disaster.  Full Article 

Essar Group

Essar Group

Exclusive - Essar's planned oil-for-steel deal tests Iran sanctions  Full Article 

Islamic Fund

Islamic Fund

India gets new Islamic equity fund but debt market still off-limits  Full Article 

Fiscal Deficit

Fiscal Deficit

April-October fiscal deficit nears 90 pct of full-year target  Full Article 

Oil Prices

Oil Prices

Oil hits new four-year low post OPEC as glut looms  Full Article 

Gold Imports

Gold Imports

India eases gold import rule in surprise move.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage